

## PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 77472

Title: Neoadjuvant immunotherapy in non-small-cell lung cancer: times are

changing – and fast

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06280646

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Italy

Author's Country/Territory: Spain

Manuscript submission date: 2022-05-09

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-05-09 09:30

Reviewer performed review: 2022-05-09 09:32

Review time: 1 Hour

Scientific quality	[Y] Grade A: Excellent [] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[Y] Accept (High priority) [] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	[ ]Yes [Y]No



Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [ ] Yes [Y] No

## SPECIFIC COMMENTS TO AUTHORS

This is a well-written letter containing interesting comments which merit publication.



## PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Oncology

Manuscript NO: 77472

**Title:** Neoadjuvant immunotherapy in non-small-cell lung cancer: times are changing – and fast

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03479519

**Position:** Editorial Board

Academic degree: FACS, FICS

Professional title: Professor, Surgeon

Reviewer's Country/Territory: Japan

Author's Country/Territory: Spain

Manuscript submission date: 2022-05-09

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-05-30 00:33

Reviewer performed review: 2022-06-07 10:29

**Review time:** 8 Days and 9 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	<ul> <li>[ ] Accept (High priority) [Y] Accept (General priority)</li> <li>[ ] Minor revision [ ] Major revision [ ] Rejection</li> </ul>
Re-review	[ ]Yes [Y]No



Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [ ] Yes [Y] No

## SPECIFIC COMMENTS TO AUTHORS

The present "Letter to the Editor" article well supplements the authors' latest article entitled "Neoadjuvant treatment in non-small cell lung cancer (NSCLC): new perspectives with the incorporation of immunotherapy", which has just been accepted for publication in World Journal of Clinical Oncology. I think this article must be of considerable interest to the readers.